血管内皮生长因子、雌激素受体在甲状腺乳头状癌和甲状腺滤泡状腺瘤组织中的表达及其意义  

The significance of expressions of vascular endothelial growth factor and estrogen receptor in papillary thyroid carcinomas and thyroid adenomas

作　　者：瓮生彬[1] 张建波[1] 张淑艳[1] 郑超[1] 白杰[1] 徐德龙[2] 

机构地区：[1]河北大学附属医院急诊外科,河北保定071000 [2]河北医科大学附属三院普外科,河北石家庄050051

出　　处：《蚌埠医学院学报》2010年第1期37-39,共3页Journal of Bengbu Medical College

摘　　要：目的:研究血管内皮生长因子(vascular endothelial growth factor,VEGF)雌激素受体(estrogen receptor,ER)在甲状腺乳头状癌和甲状腺滤泡状腺瘤及癌旁正常甲状腺组织中表达及意义,探讨两者对甲状腺乳头状癌治疗方案的制定和预后估计的临床意义。方法:对30例甲状腺乳头状癌、30例甲状腺滤泡状腺瘤和30例癌旁正常甲状腺组织,采用免疫组织化学S-P法,检测VEGF、ER表达。结果:VEGF、ER在甲状腺乳头状癌及甲状腺滤泡状腺瘤组织中的表达均有统计学意义(P<0.05),均高于癌旁正常甲状腺组织(P<0.05)。两者在甲状腺乳头状癌中的阳性表达率呈负相关关系(P<0.05)。结论:VEGF、ER的表达可作为甲状腺乳头状癌的协助诊断指标,是评价甲状腺乳头状癌和滤泡状腺瘤生物特性的重要指标,对临床治疗和预后判断具有重要的指导意义。Objective：To investigate the significance of vascular endothelial growth factor（VEGF）and estrogen receptor（ER） expressions in papillary thyroid carcinoma,thyroid follicular adenoma and adjacent normal tissues,further to study the clinical significance of these two markers in treatment strategies of thyroid carcinoma and estimating prognosis.Methods：Thirty papillary thyroid carcinomas tissues,30 thyroid follicular adenomas tissues and 30 adjacent normal tissues were collected.Immunohistochemical S-P method was used to detect the expressions of VEGF and ER.Results：The expressions of VEGF and ER in papillary thyroid carcinoma and thyroid follicular adenoma both had significant differences,and both of them were higher than that in adjacent normal tissues（P〈0.05）.The positive rate of VEGF and ER expressions in papillary thyroid carcinoma had the negative correlation（P〈0.05）.Conclusions：The expressions of VEGF and ER could be as diagnostic indexes for papillary thyroid carcinoma.They also could be as the important indexes for evaluating the biological characteristics of papillary thyroid carcinoma and thyroid follicular adenoma and had the significant guiding role for clinical treatment and prognostic analysis.

关 键 词：甲状腺肿瘤 乳头状癌 血管内皮生长因子 雌激素受体 免疫组织化学 

分 类 号：R736.1[医药卫生—肿瘤] R730.261[医药卫生—临床医学]